EMA To Bring Anticancer Drugs Guide Up To Speed With Biomarker Development
Executive Summary
Although biomarkers are increasingly being used in oncology to define malignant diseases and develop new treatment strategies, the European Medicines Agency's current guideline on evaluating anticancer drugs does not adequately address these aspects.